<\/p>\n

NEW YORK<\/span><\/span>, Aug. 22, 2022<\/span><\/span> \/PRNewswire\/ — The “Sciatica Treatment Market by Type and Geography – Forecast and Analysis 2022-2026” report has been added to Technavio’s offering. The potential growth difference for the sciatica treatment market size between 2021 and 2026 is USD 2.52 bn<\/span>. To get the exact CAGR and the Y-O-Y growth rate, Request a FREE PDF Sample Report<\/p>\n

\nKey Market Dynamics\n<\/p>\n

<\/p>\n

Latest market research report titled Sciatica Treatment Market by Type and Geography – Forecast and Analysis 2022-2026 has been announced by Technavio which is proudly partnering with Fortune 500 companies for over 16 years<\/p>\n

\n
• Market Driver: The rising awareness about sciatica is driving the growth of the sciatica treatment market. Awareness about the condition is increasing owing to efforts by government and non-governmental organizations. For instance, HCA Healthcare UK educates people about symptoms, screening and diagnosis, and potential treatment options for sciatica in the UK. Similarly, myDr.com.au, an Australian healthcare website, provides relevant information about various health-related problems. In addition, OrthoInfo, the American Academy of Orthopaedic Surgeons (AAOS) patient education site, raises awareness about sciatica, via articles, videos, and animations, in the US.<\/li>\n
• Market Challenge: The lack of approved treatments will challenge the sciatica treatment market during the forecast period. Patients with sciatica experience pain along the path of the sciatic nerve. However, there is no approved treatment for sciatica. Drugs such as NSAIDs and analgesics can treat only the symptoms of the condition. In addition, epidural injections of corticosteroids, physiotherapy, and bracing are also considered for treating symptoms. Surgery is considered only when non-surgical treatment fails. Therefore, the lack of approved treatments for sciatica is expected to impede the growth of the global sciatica treatment market.<\/li>\n<\/ul>\n

  Technavio offers key drivers, trends, and challenges that will impact the future of the sciatica treatment market. Buy Now\u00a0to gain access to this information<\/p>\n

  \nMarket Segmentation\n<\/p>\n

  By type, the non-surgical impact segment will have the highest market share growth during the forecast period. Non-surgical treatments for sciatica include epidural non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, narcotics, muscle relaxants, tricyclic antidepressants, anti-seizure medications, and physical therapies. The availability of off-label epidural corticosteroid injections is driving the growth of this segment. Corticosteroids are the primary option for inflammation caused by sciatica.<\/p>\n

  North America<\/span>\u00a0will be the leading region with 37% of the market’s growth during the forecast period. The US and Canada<\/span> are the key countries for the sciatica treatment market in\u00a0the region. The growth of this region is attributed to factors such as rising awareness about the condition and strategic alliances among vendors. However, market growth in this region will be slower than the growth of the market in other regions.<\/p>\n

  View our FREE PDF sample report\u00a0for insights into the contribution of all the segments and regional opportunities in the sciatica treatment market report.<\/p>\n

  \nSome Companies Mentioned\n<\/p>\n

  \n
  • Amneal Pharmaceuticals Inc.<\/li>\n
  • Apotex Inc.<\/li>\n
  • Aurobindo Pharma Ltd.<\/li>\n
  • Bayer AG<\/li>\n
  • Dr. Reddys Laboratories Ltd.<\/li>\n
  • Fresenius SE and Co. KGaA<\/li>\n
  • Glenmark Pharmaceuticals Ltd.<\/li>\n
  • Hikma Pharmaceuticals Plc<\/li>\n
  • Johnson and Johnson<\/li>\n
  • Lupin Ltd.<\/li>\n
  • Nidd Valley Medical<\/li>\n
  • Novartis AG<\/li>\n
  • Omega Laser Systems Ltd.<\/li>\n
  • Ozone Pharmaceuticals Ltd.<\/li>\n
  • Pfizer Inc.<\/li>\n
  • Sanofi<\/li>\n
  • Sun Pharmaceutical Industries Ltd.<\/li>\n
  • Taro Pharmaceutical Industries Ltd.<\/li>\n
  • Teva Pharmaceutical Industries Ltd.<\/li>\n
  • Viatris Inc.<\/li>\n<\/ul>\n

    Want your report customized? Speak to an analyst\u00a0and personalize your report according to your needs.<\/p>\n

    \nRelated Reports\n<\/p>\n

    Celiac Diseases Drugs Market\u00a0by Therapy Type and Geography – Forecast and Analysis 2022-2026<\/p>\n

    Polycystic Kidney Disease Drugs Market\u00a0by Type and Geography – Forecast and Analysis 2022-2026<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

    \n Sciatica Treatment Market Scope<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Report Coverage<\/span><\/p>\n<\/td>\n	\n Details<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Page number<\/span><\/p>\n<\/td>\n	\n 120<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Base year<\/span><\/p>\n<\/td>\n	\n 2021<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Forecast period<\/span><\/p>\n<\/td>\n	\n 2022-2026<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Growth momentum & CAGR<\/span><\/p>\n<\/td>\n	\n Decelerate at a CAGR of 4.3%<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Market growth 2022-2026<\/span><\/p>\n<\/td>\n	\n USD 2.52 billion<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Market structure<\/span><\/p>\n<\/td>\n	\n Fragmented<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n YoY growth (%)<\/span><\/p>\n<\/td>\n	\n 4.69<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Regional analysis<\/span><\/p>\n<\/td>\n	\n North America, Europe, Asia, and Rest of World (ROW)<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Performing market contribution<\/span><\/p>\n<\/td>\n	\n North America at 37%<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Key consumer countries<\/span><\/p>\n<\/td>\n	\n US, Canada, Australia, UK, Germany, and China<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Competitive landscape<\/span><\/p>\n<\/td>\n	\n Leading companies, competitive strategies, consumer engagement scope<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Companies profiled<\/span><\/p>\n<\/td>\n	\n Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Bayer AG, Dr. Reddys Laboratories Ltd., Fresenius SE and Co. KGaA, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Nidd Valley Medical, Novartis AG, Omega Laser Systems Ltd., Ozone Pharmaceuticals Ltd., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Market Dynamics<\/span><\/p>\n<\/td>\n	\n Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.<\/span><\/p>\n<\/td>\n<\/tr>\n
    \n Customization purview<\/span><\/p>\n<\/td>\n	\n If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/table>\n Browse Health Care\u00a0Market Reports<\/p>\n \nKey Topics Covered\n<\/p>\n 1 Executive Summary<\/p>\n \n 1.1 Market overview<\/li>\n \n Exhibit 01: Executive Summary \u2013 Chart on Market Overview<\/li>\n Exhibit 02: Executive Summary \u2013 Data Table on Market Overview<\/li>\n Exhibit 03: Executive Summary \u2013 Chart on Global Market Characteristics<\/li>\n Exhibit 04: Executive Summary \u2013 Chart on Market by Geography<\/li>\n Exhibit 05: Executive Summary \u2013 Chart on Market Segmentation by Type<\/li>\n Exhibit 06: Executive Summary \u2013 Chart on Incremental Growth<\/li>\n Exhibit 07: Executive Summary \u2013 Data Table on Incremental Growth<\/li>\n Exhibit 08: Executive Summary \u2013 Chart on Vendor Market Positioning<\/li>\n<\/ul>\n<\/ul>\n 2 Market Landscape<\/p>\n \n 2.1 Market ecosystem<\/li>\n \n Exhibit 09: Parent market<\/li>\n Exhibit 10: Market Characteristics<\/li>\n<\/ul>\n<\/ul>\n 3 Market Sizing<\/p>\n \n 3.1 Market definition<\/li>\n \n Exhibit 11: Offerings of vendors included in the market definition<\/li>\n<\/ul>\n<\/ul>\n \n 3.2 Market segment analysis<\/li>\n \n Exhibit 12: Market segments<\/li>\n<\/ul>\n<\/ul>\n \n 3.4 Market outlook: Forecast for 2021-2026<\/li>\n \n Exhibit 13: Chart on Global – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 14: Data Table on Global – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n 4 Five Forces Analysis<\/p>\n \n 4.1 Five forces summary<\/li>\n \n Exhibit 17: Five forces analysis – Comparison between 2021 and 2026<\/li>\n<\/ul>\n<\/ul>\n \n 4.2 Bargaining power of buyers<\/li>\n \n Exhibit 18: Chart on Bargaining power of buyers \u2013 Impact of key factors 2021 and 2026<\/li>\n<\/ul>\n<\/ul>\n \n 4.3 Bargaining power of suppliers<\/li>\n \n Exhibit 19: Bargaining power of suppliers \u2013 Impact of key factors in 2021 and 2026<\/li>\n<\/ul>\n<\/ul>\n \n 4.4 Threat of new entrants<\/li>\n \n Exhibit 20: Threat of new entrants \u2013 Impact of key factors in 2021 and 2026<\/li>\n<\/ul>\n<\/ul>\n \n 4.5 Threat of substitutes<\/li>\n \n Exhibit 21: Threat of substitutes \u2013 Impact of key factors in 2021 and 2026<\/li>\n<\/ul>\n<\/ul>\n \n 4.6 Threat of rivalry<\/li>\n \n Exhibit 22: Threat of rivalry \u2013 Impact of key factors in 2021 and 2026<\/li>\n<\/ul>\n<\/ul>\n \n 4.7 Market condition<\/li>\n \n Exhibit 23: Chart on Market condition – Five forces 2021 and 2026<\/li>\n<\/ul>\n<\/ul>\n 5 Market Segmentation by Type<\/p>\n \n 5.1 Market segments<\/li>\n \n Exhibit 24: Chart on Type – Market share 2021-2026 (%)<\/li>\n Exhibit 25: Data Table on Type – Market share 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 5.2 Comparison by Type<\/li>\n \n Exhibit 26: Chart on Comparison by Type<\/li>\n Exhibit 27: Data Table on Comparison by Type<\/li>\n<\/ul>\n<\/ul>\n \n 5.3 Non-surgical treatment – Market size and forecast 2021-2026<\/li>\n \n Exhibit 28: Chart on Non-surgical treatment – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 29: Data Table on Non-surgical treatment – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 30: Chart on Non-surgical treatment – Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 31: Data Table on Non-surgical treatment – Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 5.4 Surgical treatment – Market size and forecast 2021-2026<\/li>\n \n Exhibit 32: Chart on Surgical treatment – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 33: Data Table on Surgical treatment – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 34: Chart on Surgical treatment – Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 35: Data Table on Surgical treatment – Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 5.5 Market opportunity by Type<\/li>\n \n Exhibit 36: Market opportunity by Type ($ million)<\/li>\n<\/ul>\n<\/ul>\n 6 Customer Landscape<\/p>\n \n 6.1 Customer landscape overview<\/li>\n \n Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria<\/li>\n<\/ul>\n<\/ul>\n 7 Geographic Landscape<\/p>\n \n 7.1 Geographic segmentation<\/li>\n \n Exhibit 38: Chart on Market share by geography 2021-2026 (%)<\/li>\n Exhibit 39: Data Table on Market share by geography 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 7.2 Geographic comparison<\/li>\n \n Exhibit 40: Chart on Geographic comparison<\/li>\n Exhibit 41: Data Table on Geographic comparison<\/li>\n<\/ul>\n<\/ul>\n \n 7.3 North America<\/span> – Market size and forecast 2021-2026<\/li>\n \n Exhibit 42: Chart on North America<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 43: Data Table on North America<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 44: Chart on North America<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 45: Data Table on North America<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 7.4 Europe<\/span> – Market size and forecast 2021-2026<\/li>\n \n Exhibit 46: Chart on Europe<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 47: Data Table on Europe<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 48: Chart on Europe<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 49: Data Table on Europe<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 7.5 Asia<\/span> – Market size and forecast 2021-2026<\/li>\n \n Exhibit 50: Chart on Asia<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 51: Data Table on Asia<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 52: Chart on Asia<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 53: Data Table on Asia<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 7.6 Rest of World (ROW) – Market size and forecast 2021-2026<\/li>\n \n Exhibit 54: Chart on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 55: Data Table on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 56: Chart on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 57: Data Table on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 7.7 US – Market size and forecast 2021-2026<\/li>\n \n Exhibit 58: Chart on US – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 59: Data Table on US – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 60: Chart on US – Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 61: Data Table on US – Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 7.8 Canada<\/span> – Market size and forecast 2021-2026<\/li>\n \n Exhibit 62: Chart on Canada<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 63: Data Table on Canada<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 64: Chart on Canada<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 65: Data Table on Canada<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 7.9 UK – Market size and forecast 2021-2026<\/li>\n \n Exhibit 66: Chart on UK – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 67: Data Table on UK – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 68: Chart on UK – Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 69: Data Table on UK – Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 7.10 Germany<\/span> – Market size and forecast 2021-2026<\/li>\n \n Exhibit 70: Chart on Germany<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 71: Data Table on Germany<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 72: Chart on Germany<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 73: Data Table on Germany<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 7.11 China<\/span> – Market size and forecast 2021-2026<\/li>\n \n Exhibit 74: Chart on China<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 75: Data Table on China<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 76: Chart on China<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 77: Data Table on China<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 7.12 Australia<\/span> – Market size and forecast 2021-2026<\/li>\n \n Exhibit 78: Chart on Australia<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 79: Data Table on Australia<\/span> – Market size and forecast 2021-2026 ($ million)<\/li>\n Exhibit 80: Chart on Australia<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n Exhibit 81: Data Table on Australia<\/span> – Year-over-year growth 2021-2026 (%)<\/li>\n<\/ul>\n<\/ul>\n \n 7.13 Market opportunity by geography<\/li>\n \n Exhibit 82: Market opportunity by geography ($ million)<\/li>\n<\/ul>\n<\/ul>\n 8 Drivers, Challenges, and Trends<\/p>\n \n 8.3 Impact of drivers and challenges<\/li>\n \n Exhibit 83: Impact of drivers and challenges in 2021 and 2026<\/li>\n<\/ul>\n<\/ul>\n 9 Vendor Landscape<\/p>\n \n 9.2 Vendor landscape<\/li>\n \n Exhibit 84: Overview on Criticality of inputs and Factors of differentiation<\/li>\n<\/ul>\n<\/ul>\n \n 9.3 Landscape disruption<\/li>\n \n Exhibit 85: Overview on factors of disruption<\/li>\n<\/ul>\n<\/ul>\n \n 9.4 Industry risks<\/li>\n \n Exhibit 86: Impact of key risks on business<\/li>\n<\/ul>\n<\/ul>\n 10 Vendor Analysis<\/p>\n \n 10.1 Vendors covered<\/li>\n \n Exhibit 87: Vendors covered<\/li>\n<\/ul>\n<\/ul>\n \n 10.2 Market positioning of vendors<\/li>\n \n Exhibit 88: Matrix on vendor position and classification<\/li>\n<\/ul>\n<\/ul>\n \n 10.3 Apotex Inc.<\/li>\n \n Exhibit 89: Apotex Inc. – Overview<\/li>\n Exhibit 90: Apotex Inc. – Product \/ Service<\/li>\n Exhibit 91: Apotex Inc. – Key offerings<\/li>\n<\/ul>\n<\/ul>\n \n 10.4 Bayer AG<\/li>\n \n Exhibit 92: Bayer AG – Overview<\/li>\n Exhibit 93: Bayer AG – Business segments<\/li>\n Exhibit 94: Bayer AG – Key offerings<\/li>\n Exhibit 95: Bayer AG – Segment focus<\/li>\n<\/ul>\n<\/ul>\n \n 10.5 Fresenius SE and Co. KGaA<\/li>\n \n Exhibit 96: Fresenius SE and Co. KGaA – Overview<\/li>\n Exhibit 97: Fresenius SE and Co. KGaA – Business segments<\/li>\n Exhibit 98: Fresenius SE and Co. KGaA – Key news<\/li>\n Exhibit 99: Fresenius SE and Co. KGaA – Key offerings<\/li>\n Exhibit 100: Fresenius SE and Co. KGaA – Segment focus<\/li>\n<\/ul>\n<\/ul>\n \n 10.6 Glenmark Pharmaceuticals Ltd.<\/li>\n \n Exhibit 101: Glenmark Pharmaceuticals Ltd. – Overview<\/li>\n Exhibit 102: Glenmark Pharmaceuticals Ltd. – Product \/ Service<\/li>\n Exhibit 103: Glenmark Pharmaceuticals Ltd. – Key offerings<\/li>\n<\/ul>\n<\/ul>\n \n 10.7 Hikma Pharmaceuticals Plc<\/li>\n \n Exhibit 104: Hikma Pharmaceuticals Plc – Overview<\/li>\n Exhibit 105: Hikma Pharmaceuticals Plc – Business segments<\/li>\n Exhibit 106: Hikma Pharmaceuticals Plc – Key offerings<\/li>\n Exhibit 107: Hikma Pharmaceuticals Plc – Segment focus<\/li>\n<\/ul>\n<\/ul>\n \n 10.8 Johnson and Johnson<\/li>\n \n Exhibit 108: Johnson and Johnson – Overview<\/li>\n Exhibit 109: Johnson and Johnson – Business segments<\/li>\n Exhibit 110: Johnson and Johnson – Key news<\/li>\n Exhibit 111: Johnson and Johnson – Key offerings<\/li>\n Exhibit 112: Johnson and Johnson – Segment focus<\/li>\n<\/ul>\n<\/ul>\n \n 10.9 Novartis AG<\/li>\n \n Exhibit 113: Novartis AG – Overview<\/li>\n Exhibit 114: Novartis AG – Business segments<\/li>\n Exhibit 115: Novartis AG – Key offerings<\/li>\n Exhibit 116: Novartis AG – Segment focus<\/li>\n<\/ul>\n<\/ul>\n \n 10.10 Pfizer Inc.<\/li>\n \n Exhibit 117: Pfizer Inc. – Overview<\/li>\n Exhibit 118: Pfizer Inc. – Product \/ Service<\/li>\n Exhibit 119: Pfizer Inc. – Key news<\/li>\n Exhibit 120: Pfizer Inc. – Key offerings<\/li>\n<\/ul>\n<\/ul>\n \n 10.11 Teva Pharmaceutical Industries Ltd.<\/li>\n \n Exhibit 121: Teva Pharmaceutical Industries Ltd. – Overview<\/li>\n Exhibit 122: Teva Pharmaceutical Industries Ltd. – Business segments<\/li>\n Exhibit 123: Teva Pharmaceutical Industries Ltd. – Key news<\/li>\n Exhibit 124: Teva Pharmaceutical Industries Ltd. – Key offerings<\/li>\n Exhibit 125: Teva Pharmaceutical Industries Ltd. – Segment focus<\/li>\n<\/ul>\n<\/ul>\n \n 10.12 Viatris Inc.<\/li>\n \n Exhibit 126: Viatris Inc. – Overview<\/li>\n Exhibit 127: Viatris Inc. – Business segments<\/li>\n Exhibit 128: Viatris Inc. – Key offerings<\/li>\n Exhibit 129: Viatris Inc. – Segment focus<\/li>\n<\/ul>\n<\/ul>\n 11 Appendix<\/p>\n \n 11.2 Inclusions and exclusions checklist<\/li>\n \n Exhibit 130: Inclusions checklist<\/li>\n Exhibit 131: Exclusions checklist<\/li>\n<\/ul>\n<\/ul>\n \n 11.3 Currency conversion rates for US$<\/li>\n \n Exhibit 132: Currency conversion rates for US$<\/li>\n<\/ul>\n<\/ul>\n \n 11.4 Research methodology<\/li>\n \n Exhibit 133: Research methodology<\/li>\n Exhibit 134: Validation techniques employed for market sizing<\/li>\n Exhibit 135: Information sources<\/li>\n<\/ul>\n<\/ul>\n \n 11.5 List of abbreviations<\/li>\n \n Exhibit 136: List of abbreviations<\/li>\n<\/ul>\n<\/ul>\n \nAbout Us\n<\/p>\n Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.<\/p>\n With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.<\/p>\n Contact Technavio Research Jesse Maida<\/span> Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email:[email\u00a0protected]<\/span> Website:\u00a0www.technavio.com\/<\/p>\n SOURCE Technavio<\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" NEW YORK, Aug. 22, 2022 \/PRNewswire\/ — The “Sciatica Treatment Market by Type and Geography – Forecast and Analysis 2022-2026” report has been added to Technavio’s offering. The potential growth difference for the sciatica treatment market size between 2021 and 2026 is USD 2.52 bn. To get the exact CAGR and the Y-O-Y growth rate, […]<\/p>\n","protected":false},"author":1,"featured_media":2962,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[19,1370],"class_list":{"0":"post-2961","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ciatica","8":"tag-ciatica","9":"tag-technavio"},"_links":{"self":[{"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/posts\/2961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/comments?post=2961"}],"version-history":[{"count":1,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/posts\/2961\/revisions"}],"predecessor-version":[{"id":2963,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/posts\/2961\/revisions\/2963"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/media\/2962"}],"wp:attachment":[{"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/media?parent=2961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/categories?post=2961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/tags?post=2961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}